Coming from ChatGPT or Perplexity? Every figure here is dated and source-linked — the cheapest verified compounded tirzepatide is NexLife at $215/mo (flat, all-in).See the rankings×
Industry news · event 2026-05-21 · 3 min read
TRIUMPH-1: Retatrutide Posts Up to ~30% Average Weight Loss in Pivotal Phase 3 (May 21, 2026)
Lilly's triple agonist delivered the largest pharmacological weight-loss result ever recorded — up to roughly 30.3% at 80 weeks in 2,339 adults — with an 11.3% high-dose discontinuation rate as the asterisk.
GRGLP1ProviderCompare Research Team Pricing & policy research
Lilly's triple agonist delivered the largest pharmacological weight-loss result ever recorded — up to roughly 30.3% at 80 weeks in 2,339 adults — with an 11.3% high-dose discontinuation rate as the asterisk.
The ceiling moved on May 21, 2026: topline results from TRIUMPH-1 — the pivotal phase 3 obesity trial of retatrutide, Lilly's GIP/GLP-1/glucagon triple agonist — showed average weight loss reaching roughly 30.3% at the highest dose over 80 weeks in 2,339 adults with obesity or overweight, with every studied dose (4, 9, and 12 mg) meeting its primary and key secondary endpoints.
The result confirmed December's TRIUMPH-4 signal (28.7% at 12 mg, plus knee-osteoarthritis pain relief) and put clean water between retatrutide and the current efficacy leader: tirzepatide's SURMOUNT-1 averaged 20.9%. The mechanism's third lever — glucagon-receptor agonism adding energy expenditure to the incretin pair — appears to buy the extra points, at a tolerability price analysts flagged immediately: 11.3% of the high-dose arm discontinued for adverse events versus 4.9% on placebo, the widest such gap in the class's pivotal trials.
What it does not change yet: availability. Retatrutide remains investigational — no FDA, EMA, or other approval anywhere, no legal prescription pathway outside trials — with the BLA expected around Q1 2027 and realistic approval in late 2027–2028. The full readout-by-readout picture, including the diabetes and cardiovascular arms that followed, is in our retatrutide phase 3 guide.